COMMUNIQUÉS West-GlobeNewswire

Iovance Biotherapeutics to Present at Upcoming Conference
21/05/2026
SAN CARLOS, Calif., May 21, 2026 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte [...]
Micron Biomedical Celebrates the Grand Opening of Its Commercial-Scale Manufacturing Site in Georgia
21/05/2026
National and local leaders across government, investors, life science industry and academia acknowledge the impact of Micron’s dissolvable vaccines and therapies on human health and economic development ALPHARETTA, Ga [...]
Akari Therapeutics Announces $5.5 Million Private Placement Offering
21/05/2026
TAMPA, Fla. and LONDON, May 21, 2026 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), an oncology biotechnology company developing antibody drug conjugates (ADCs) with a novel RNA splicing modulator payload, [...]
Realize Medical Appoints Entrepreneur and Investor Tom Kaneb to Board of Directors
21/05/2026
OTTAWA, Ontario, May 21, 2026 (GLOBE NEWSWIRE) -- Realize Medical , a global leader in immersive medical imaging and virtual reality solutions for surgical planning and medical collaboration, today announced the [...]
NewGenIVF Announces Strategic Investment Agreement with Tech Veteran Andy Cheung-Led K25.ai, an AI-Powered Live-Streaming Prediction Market, at US$100 Million Valuation
21/05/2026
Initial US$2 million strategic investment values K25.ai at US$100 million pre-money, with option to invest up to US$10 million if exercised in full; exclusive APAC agency partnership provides NewGenIVF with exposure to [...]
Genvor Appoints Donald Kalkofen as Chief Financial Officer
21/05/2026
Seasoned biotech CFO brings 20+ years of public company finance leadership and IPO experience to support Genvor’s dual-market growth strategy Woodland, CA, May 21, 2026 (GLOBE NEWSWIRE) -- Genvor, Inc. (OTCQB: GNVR) (“ [...]
Corbus Pharmaceuticals Announces the Appointment of Nishant Saxena as Chief Business Officer and Schedules a Pre-2026 ASCO CRB-701 Data Conference Call
21/05/2026
NORWOOD, Mass., May 21, 2026 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (Nasdaq: CRBP), a clinical-stage company focused on developing promising new therapies in oncology and obesity, today announced that [...]
‘Pour La Passe’: Haleon Canada lance une campagne nationale avec Canada Soccer pour célébrer les petits gestes de santé derrière le bien-être des Canadiens
21/05/2026
Une nouvelle campagne publicitaire de Haleon Canada, mettant en vedette Richie Laryea, donne vie une campagne intégrée qui englobe les médias, le commerce de détail et une tournée expérientielle à travers le pays [...]
Nanobiotix Announces Trading Resumption of Its Ordinary Shares on Euronext Paris
21/05/2026
PARIS and CAMBRIDGE, Mass., May 21, 2026 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO – NASDAQ: NBTX – “ Nanobiotix ” or the “ Company ”), a late-clinical stage biotechnology company pioneering physics-based [...]
Brain Cancer Canada Awards The Dwayne Andrews Glioblastoma Research Grant to Tackle One of the Most Aggressive Brain Tumours and Unlock Immunotherapy Breakthroughs for Young Patients
21/05/2026
TORONTO, May 21, 2026 (GLOBE NEWSWIRE) -- Brain Cancer Canada (BCC), the country’s only 100% volunteer-driven charity dedicated exclusively to funding brain cancer research nationwide, is proud to award $50,000 through [...]
Nanobiotix Announces Pricing of Oversubscribed €85m Global Offering
21/05/2026
PARIS, France and CAMBRIDGE, Mass., May 21, 2026 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO – NASDAQ: NBTX – “ Nanobiotix ” or the “ Company ”), a late-clinical stage biotechnology company pioneering physics-based [...]
CytomX Therapeutics to Present at Upcoming June Investor Conferences
21/05/2026
SOUTH SAN FRANCISCO, Calif., May 21, 2026 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of masked, conditionally activated biologics, today announced that management will [...]
Biodesix to Participate in Upcoming Investor Conferences
21/05/2026
LOUISVILLE, Colo., May 21, 2026 (GLOBE NEWSWIRE) -- Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostics solutions company, today announced that members of the Biodesix leadership team will participate in three upcoming [...]
Infex Therapeutics announces positive Phase IIa results for RESP-X in non-cystic fibrosis bronchiectasis patients colonised with Pseudomonas aeruginosa
21/05/2026
Study met its primary objective demonstrating excellent safety and tolerability, of RESP-X in patients with NCFB colonised with Pseudomonas aeruginosa ( Pa ) Secondary objectives met with no immunogenicity observed, [...]
Immix Biopharma Announces 95% Complete Response Rate in Interim Update From relapsed/refractory AL Amyloidosis Clinical Trial NEXICART-2
21/05/2026
– Of first 20 patients, all four MRD-negative patients have converted to complete response (CR) – – CR rate now 95% (19 of 20 patients) – – All CRs reached within 1 year of follow-up post-dosing – – No relapses to-date [...]
Weight Loss Coaching vs. App-Only Programs: What Published Research Shows About Long-Term Outcomes
21/05/2026
70% of users discontinued use of lifestyle behavior and health apps within the first 100 days (Kidman PG, et al., 2024) Early weight loss at week four is a strong predictor of clinically relevant outcomes, with research [...]
Hemab Therapeutics Reports First Quarter 2026 Financial Results
21/05/2026
Completed Initial Public Offering in May 2026, raising gross proceeds of $346.7 million and listing on Nasdaq Granted Breakthrough Therapy Designation for sutacimig in Glanzmann thrombasthenia CAMBRIDGE, Mass. and [...]
Immix Biopharma Announces Pricing of $150 Million Underwritten Offering of Common Stock
21/05/2026
LOS ANGELES, May 21, 2026 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (“ImmixBio”, “Company”, “We” or “Us” or “IMMX”), a global leader in AL Amyloidosis, today announced the pricing of an underwritten registered offering [...]
HUTCHMED and Innovent Jointly Announce NMPA Approval for ELUNATE® (Fruquintinib) in Combination with TYVYT® (Sintilimab Injection) for the Treatment of Patients with Locally Advanced or Metastatic Renal Cell Carcinoma
21/05/2026
Reduced risk of disease progression or death by 63%, with median PFS of 22.2 months in the FRUSICA-2 registration study HONG KONG and SHANGHAI and FLORHAM PARK, N.J., May 21, 2026 (GLOBE NEWSWIRE) -- HUTCHMED (China) [...]

Pages